Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement ...

Pheton is just the latest example of wild trading moves seen in Chinese companies that trade on Nasdaq. Read more at straitstimes.com. Read more at straitstimes.com.

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

Thursday closed down -0.37%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.74%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.55%. September E-mini S&P futures (ESU25) fell ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...